Progression-free survival (PFS) and overall survival (OS) patients with metastatic colorectal cancer treated with bevacizumab, grouped according to serum carcinoembryonic antigen (CEA) level. The gene discussed is CEACAM5; the disease is metastatic colorectal cancer.